Hormonal counterregulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy

European Journal of Clinical Pharmacology

Volumn 59, Issue 10, 2003, Pages 747-754

  Holstein, A ^a   Plaschke, A ^a   Hammer, C ^a   Ptak, M ^a   Kuhn, J ^b   Kratzsch, C ^c   Diekmann, J ^b   Kleesiek, K ^b   Maurer, H H ^c   Egberts, E H ^a  

^a KLINIKUM LIPPE DETMOLD   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Glimepiride; Hypoglycaemia counterregulation; Sulphonylurea

Indexed keywords

ADRENALIN; ANALGESIC AGENT; C PEPTIDE; CORTICOTROPIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIMEPIRIDE; GLUCAGON; GLUCOSE; GROWTH HORMONE; HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; NEUROTROPIC AGENT; NORADRENALIN; PANCREAS POLYPEPTIDE; SEDATIVE AGENT; SULFONYLUREA DERIVATIVE;

AGED; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; MALE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REGULATORY MECHANISM;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; HORMONES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 9144261133     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0697-9     Document Type: Article

References (33)

1. Sugarman JR (1991) Hypoglycemia associated hospitalizations in a population with a high prevalence of non-insulin-dependent diabetes mellitus. Diab Res Clin Pract 14:139-148
2. Bachmann W, Löbe A, Lacher F (1995) Medikamentös bedingte Hypoglykämien bei Typ-II-Diabetes. Diabetes und Stoffwechsel 4:83-89
3. Asplund K, Wiholm B-E, Lithner F (1983) Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 24:412-417
4. Holstein A, Plaschke A, Egberts E-H (2001) Lower incidence of severe hypoglycaemia in type 2 diabetic patients treated with glimepiride versus glibenclamide. Diab Metabol Res Rev 17:467-473
5. Holstein A, Plaschke A, Hammer C, Egberts E-H (2003) Characteristics and time course of severe glimepiride- versus glibenclamide induced hypoglycaemia. Eur J Clin Pharmacol 59:91-97
6. Stahl M, Berger W (1999) Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 16:586-590
7. Spyer G, Hattersley AT, MacDonald IA, Amiel S, MacLeod KM (2000) Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes. Lancet 356:1970-1974
8. Meneilly GS, Cheung E, Tuokko H (1994) Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 43:4403-4409
9. Holstein A, Plaschke A, Vogel Y-M, Egberts E-H (2003) Prehospital management of diabetic emergencies - a population-based intervention study. Acta Anaesthesiol Scand 47:610-615
10. Sills MN, Ogu CC, Maxa J (1997) Prolonged hypoglycemic crisis associated with glyburide. Pharmacotherapy 17:1338-1340
11. Krepinsky J, Ingram AJ, Clase CM (2000) Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 35:500-505
12. Cockroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
13. Maurer HH, Kratzsch C, Kraemer T, Peters FT, Weber AA (2002). Screening, library-assisted identification and validated quantification of oral antidiabetics of the sulfonylurea-type in plasma by atmospheric pressure chemical ionization liquid chromatography-mass spectrometry. J Chromatogr B 773:63-73
14. Strachan MW, Abraha HD, Sherwood RA, Lammie GA, Deary IJ, Ewing FM, Perros P, Frier BM (1999) Evaluation of serum markers of neuronal damage following severe hypoglycaemia in adults with insulin-treated diabetes mellitus. Diabetes Metab Res Rev 15:5-12
15. McAulay V, Deary IJ, Frier BM (2001) Symptoms of hypoglycaemia in people with diabetes. Diabet Med 18:690-705
16. Heller SR, Macdonald IA, Tattersall RB (1987) Counterregulation in Type II (non-insulin-dependent) diabetes mellitus. Normal endocrine and glycaemic responses, up to ten years after diagnosis. Diabetologia 30:924-929
17. Peacey SR, George E, Rostami-Hodjegan A, Bedford C, Harris N, Hardisty CA, Tucker GT, Macdonald IA, Heller SR (1996) Similar physiological and symptomatic responses to sulphonylurea and insulin induced hypoglycaemia in normal subjects. Diabet Med 13:634-641
18. Shamoon H, Friedman S, Canton C, Zacharowicz L, Hu M, Rossettti L (1994) Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus. J Clin Invest 93:2562-2571
19. Landstedt-Hallin L, Adamson U, Lins PE (1999) Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 84:3140-3145
20. Segel SA, Paramore DS, Cryer PE (2002) Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 51:724-733
21. Harrigan RA, Nathan MS, Beattie P (2001) Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med 38:68-78
22. Rydberg T, Wahlin-Boll E, Melander A (1991) Determination of glibenclamide and ist two major metabolites in human serum and urine by column liquid chromatography. Chromatography 564:223-233
23. Badian M, Korn A, Lehr K-H, Malerczyk V, Waldhäusl W (1996) Pharmacokinetics and pharmacodynamics of the hydroxy-metabolite of glimepiride (Amaryl) after intravenous administration. Drug Metab Drug Interact 13:69-85
24. Kirchheiner J, Brockmöller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I (2002) Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 71:286-296
25. Schwanstecher M, Sieverding C, Dorschner H, Gross I, Aguilar-Bryan L, Schwanstecher C, Bryan J (1998) Potassium channel openers require ATP to bind to and act through sulfonylurea receptors. EMBO J 17:5529-5535
26. Dorschner H, Brekardin E, Uhde I, Schwanstecher C, Schwanstecher M (1999) Stoichometry of sulfonylurea-induced ATP-sensitive potassium channel closure. Mol Pharmacol 55:1060-1066
27. Song DK, Ashcroft FM (2001) Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J Pharmacol 133:193-199
28. Müller G, Hartz D, Pünter J, Ökonomopulos R, Kramer W (1994) Differential interaction of glimepiride and glibenclamide with the β-cell-sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1191:267-277
29. Kramer W, Müller G, Geisen K (1996) Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at β-cells. Horm Metab Res 28:464-468
30. Balant L, Zahnd GR, Weber F, Fabre J (1977) Behaviour of glibenclamide on repeated administration to diabetic patients. Eur J Clin Pharmacol 11:19-25
31. Hellman B, Schlin J, Täljedal IB (1984) Glibenclamide is exceptional among in hypoglycaemic sulphonylureas in accumulating progressively in β-cell-rich islets. Acta Endocr 105:385-390
32. Melander A, Donelly R, Rydberg T (1998) Is there a concentration-effect relationship for sulphonylureas? Clin Pharmacokinet 34:181-188
33. Kwong PY, Teale JD (2002) Screening for sulphonylureas in the investigation of hypoglycaemia. J Roy Soc Med 95:381-385